05/15/23 7:58 AMNYSE : EBS acquisitionEmergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian NordicEmergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At closing Emergent received $270 million, subject to customary closing adjustments, and may receive up toRHEA-AIneutral
05/11/23 6:30 AMNYSE : EBS acquisitionEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUALRHEA-AIneutral
05/09/23 4:05 PMNYSE : EBS acquisitionearningsEmergent BioSolutions Reports Financial Results For First Quarter 2023Emergent BioSolutions Inc. (NYSE: EBS) today reportedRHEA-AIneutral
04/19/23 4:05 PMNYSE : EBS earningsEmergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the secondRHEA-AIneutral
03/29/23 9:48 AMNYSE : EBS fda approvalU.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency TreatmentNARCAN ® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access Expected over-the-counter availability is anticipated by late summer of this yearRHEA-AIpositive
02/27/23 4:42 PMNYSE : EBS earningsEmergent BioSolutions Reports Financial Results for Fourth Quarter 2022Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidance Reports Q4 2022 net loss of $88M and FY 2022 net loss of $224M Reports Q4 2022 adjusted EBITDA of $34M and FY 2022 adjusted EBITDA of $26M, in line with prior guidance Reports Q4 2022RHEA-AIneutral
02/15/23 5:19 PMNYSE : EBS Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter UseToday, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Administration (FDA)RHEA-AIneutral
02/15/23 2:00 AMNYSE : EBS Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 MillionEmergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. UnderRHEA-AIneutral
02/06/23 4:05 PMNYSE : EBS earningsEmergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, February 27, 2023, at 5:00 pm eastern time to discuss the financial results for the fourth quarter of 2022, recent business developments, and financial outlook forRHEA-AIneutral
01/09/23 6:59 AMNYSE : EBS Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and enhancing life through its core businesses, consisting of medical countermeasures (MCM) and commercialRHEA-AIneutral